Global ETD Search
Search theses and dissertations gathered from participating repositories worldwide. Every result links back to the library that holds it. No account is needed.
Results
Showing 1 to 19 of 19 for “"DMXAA"”.
-
Using the MDA-MB-231/EGFP-Luc2 breast cancer model to explore novel treatments for osteolytic metastases.
… the use of the vascular disrupting agent (VDA), DMXAA, either alone, or used in combination with the pan-PI3K inhibitor, GDC-0941. DMXAA, an agent of the flavonoid class, has been shown to disrupt the tumour vasculature in a number of model systems by selectively inducing apoptosis in tumour …
-
Relationship of Thalidomide Pharmacokinetics and Anti-Cancer Activity
… activity of another anti-vascular agent, DMXAA, and to modulate DMXAA-induced tumour necrosis factor (TNF) production in mice. No enantioselectivity was observed, with R- and S- enantiomers of both 3- fluorothalidomide and 3-methylthalidomide being able to inhibit TNF production and …
-
Distribution of anti-cancer drugs in solid tumours studied by MALDI-MSI.
… cancers. 5,6 -dimethylxanthenone-4-acetic acid (DMXAA) is a low molecular weight drug of the flavonoid group which has an anti-vascular effect in tumours causing endothelial cell apoptosis and activation of cytokines.A study employing matrix assisted laser desorption ionisation-mass spectrometry …
-
Investigating the effects of cGAS-STING-dependent innate immune responses in BRCA2-deficient cells
… innate immune responses using the STING agonist DMXAA in two BRCA2-deficient cell models. DMXAA treatment activated the cGAS-STING signalling pathway in only one of the BRCA2-deficient cell models, characterised by an increase in IRF3 phosphorylation, but this did not lead to an increase in DNA …
-
Targeting the Tumour Stroma for the Treatment of Melanoma
… effects of 5,6-dimethylxanthenone-4-acetic acid (DMXAA) were examined in a xenograft (A375) model and syngeneic (B16) murine models of melanoma. Antitumour activity was assessed by growth inhibition studies and histology. Immunofluorescence-based techniques, including flow cytometry and …
-
Investigating Murine Models of Non Small Cell Lung Cancer
… (VDA) 5,6-dimethylxanthenone-4-acetic acid (DMXAA) using subcutaneous, metastatic and spontaneously-derived lung adenocarcinomas. We found that despite the similar genetic background of the tumors, macrophage infiltration differed between tumor sites, and this appeared to result in …
-
Vascular Targeted Agents for the Treatment of Angiosarcoma
… inhibitor, selumetinib a MEK inhibitor, and DMXAA a vascular disrupting agent. Immunohistochemistry studies measured the expression of angiogenic growth factors in angiosarcoma tumour specimens using benign vascular lesions for comparison, and assessed canine angiosarcoma as a model of human …
-
Investigating the Stimulator of Interferon Genes Pathway as a Translational Immunogenic Therapy for Soft Tissue Sarcoma
… (STING) pathway using the murine STING agonist DMXAA, elicited immune mediated UPS clearance in 50-75% of treated mice. To assess the translational potential of STING immunotherapy, I tested the anti-tumor efficacy of three STING agonists in the KP model of UPS capable of activating both human …
-
Discovery and development of imaging-capable bacterial nitroreductases and their cytotoxic prodrugs for Clostridium sporogenes based gene therapy
… treated with vascular disrupting agent DMXAA (5,6-dimethylxanthenone-4-acetic acid) produced widespread tumour necrosis and promoted colonisation of nitroreductase expressing Clostridia spores. The combination of DMXAA and Clostridia spores alone produced significant anti-tumour activity …
-
In vivo manipulation of Fc gamma Receptor expression and activity through macrophage polarization
… Using the potent IRF3 activator and STING ligand DMXAA we were able to overcome tumour mediated suppression and recover mAb activity. Consistent with these data, DMXAA combined with anti-mouse CD20 mAb 18B12 markedly enhanced survival in the BCL1 lymphoma model leading to cures in ~80-90% of …
-
STING mediates neurodegeneration and neuroinflammation in nigrostriatal α-synucleinopathy
… agonist 5,6-dimethylxanthenone-4-acetic acid (DMXAA). Collectively, our results suggest that STING activation contributes to both neuroinflammation and neurodegeneration arising from α-synucleinopathy in PD.
-
Thalidomide Metabolism and Metabolites
… peripheral blood leucocytes, and to modulate DMXAA-induced TNF production and antitumour activity in mice. One of the three, N-(o-carboxybenzoyl)glutamic acid imide (CG) was found to be as active as thalidomide in all the assays at concentrations (1-2 μg/ml) that are achievable in MMPs. Since …
-
Combination of STING and TLR 7/8 agonists as vaccine adjuvants for cancer immunotherapy
… of combining 522, a TLR 7/8 agonist, and DMXAA, a STING agonist, to stimulate an immune response in APCs. Using flow cytometry and ELISA, we investigated the costimulatory molecule expression and cytokine secretion in dendritic cells, and M2 to M1 polarization after treatment with the …
-
Radiation-induced inflammatory responses in carcinogenesis and cardiac disease
… Results from treatment with a STING agonist (DMXAA) at tumour initiation were complex, revealing a decrease in tumour numbers, but an increase in tumour burden. In established lung tumours, T-cell exclusion was observed 7 days after irradiation, along with indications of chronic inflammation …
-
Investigating a Potential STING Modulator
The work contained in this thesis introduces a protein known as STING, an acronym for STimulator of INnterferon Genes, an immunosurveillance ER-membrane bound adapter protein critical to regulating the innate immune response in humans. The first chapter provides an overview of the STING pathway, …
-
Developing an in Vivo Reporter System for Murine CXCL1 Gene Expression, and Studying the Consequences of STING Activation on T Lymphocytes.
Our lab generated CXCL1-Luc2-RFP reporter mouse and its K-rasLA1/+ cross to provide the means for BLI and intravital imaging of spontaneously arising K-ras driven lung tumours, using a transgenic animal model that closely recapitulates human lung tumourigenesis. CXCL1 (KC) chemokine promoter …